Inhibitor for the Diagnosis and Treatment of Metastatic Cancer
Background:
The National Cancer Institute's
Laboratory of Population Genetics is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize screening
markers for early diagnosis of metastasis. Advantages of this
technology include:
- Simple PCR-based assay for detecting single
nucleotide polymorphisms (SNPs) within the Sipa-1 gene.
- Method for diagnosing early onset of
metastasis with Sipa-1.
- Sipa-1 as a new therapeutic target for
treatment of metastatic cancer.
- Inhibitors of Sipa-1 are known in the art,
they can be easily screened from existing small molecule
libraries.
Technology:
This technology results from the
identification of a new gene, Sipa-1, as a possible metastasis
modifying gene. Further analyses revealed that Sipa-1 expression
levels correlate with metastasis. Inhibitors that modulate the
Sipa-1 expression and reduce metastasis in animal models have been
identified. Additionally, single nucleotide polymorphisms (SNPs)
present in the mouse Sipa-1 gene have been identified that, if also
present in humans, could serve as the basis for diagnosing cancer
and metastasis. The technology is currently in the pre-clinical
stage of development. Laboratory data shows single nucleotide
polymorphisms (SNPs) within the Sipa-1 gene linked to metastatic
disease. Proof of concept results show that inhibition of Sipa-1
reduces metastasis in mouse models.
IP Status:
- U.S. Provisional Application filed in February, 2005.
- PCT Application was filed February, 2006.
- PCT Publication No. WO 2006084027, published October 8,
2006.
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #494 BW
Updated 10/29/2007
This opportunity is also listed under the following categories: